A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalation

AU-007 - Aulos Biosci

https://jitc.bmj.com/content/11/Suppl_1/A812

Sophia Frentzas1; Elizabeth Ahern2; Andrew Weickhardt3; Andrew Haydon4; John Powderly5; Drew Rasco6; Meredith McKean7; Paul de Souza8; Timothy Wyant9; Jenny Tang10; Lori Richards10; Aron Knickerbocker10; Inbar Amit11; Yanay Ofran11; James Vasselli12

Sep 27, 2023